Hormonal
Combining GLP-1 receptor agonists with SGLT2 inhibitors produces additive weight loss by reducing caloric intake (GLP-1) and increasing caloric excretion via glucosuria (SGLT2).
Combining a GLP-1 drug (like Byetta/Bydureon) with an SGLT2 inhibitor (like Farxiga/Jardiance) can lead to greater weight loss than either drug alone. The GLP-1 reduces hunger, while the SGLT2 causes you to excrete sugar in your urine, burning calories. This combination is often used for Type 2 Diabetes but can aid weight loss. Be mindful of potential genital yeast infections or UTIs, which are common side effects of SGLT2 inhibitors.
The combined action of SGLT2 inhibitors to cause caloric loss via glucosuria, with the GLP-1 receptor agonist to reduce appetite and caloric intake, presumably leads to additive effects on weight reduction.
Why this rating
Based on clinical trials comparing combination therapy to monotherapies; evidence is consistent but from smaller sample sizes than the major GLP-1 trials.
Source
New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review
Agni Kakouri et al. · Pharmaceuticals · 2021
DOI 10.3390/ph14090869
More from this paper
- Combination incretin therapies (GLP-1/GIP, GLP-1/Glucagon, or GLP-1/GIP/Glucagon) produce superior weight loss and glycemic control compared to monotherapy GLP-1 receptor agonists by targeting multiple hormonal pathways simultaneously.Moderate
- Dual GLP-1/Glucagon receptor agonists (e.g., Cotadutide, Oxyntomodulin) promote weight loss by combining appetite suppression (GLP-1) with increased energy expenditure (Glucagon).Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →